Fort Worth Star-Telegram

CAGE Bio Announces Positive Topline Results From its Double-Blind Phase 2 Study Evaluating an Ionic Liquid formulation of 1% Tofacitinib In Patients with Atopic Dermatitis

SAN CARLOS, CA and FORT WORTH, TX / ACCESSWIRE / August 3, 2023 / CAGE Bio, Inc. (hereinafter "CAGE Bio") a biotechnology company focused on developing innovative drug therapies for localized ...
NBC4 Columbus

CAGE Bio Announces Collaboration to Advance First-in-Class Treatments for Cutaneous Graft versus Host Disease

SAN CARLOS, Calif. and DALLAS, Aug. 27, 2025 /PRNewswire/ -- CAGE Bio Inc., a leader in advancing innovative therapies for targeted and localized treatment of immunological skin diseases, today ...
KRQE Blogs

CAGE Bio Announces Phase 2b Trial for CGB-500 (1% Tofacitinib), a Breakthrough Topical JAK Inhibitor for Moderate to Severe Atopic Dermatitis

SAN CARLOS, CA and FORT WORTH, TX / ACCESSWIRE / January 9, 2025 / CAGE Bio, Inc., a clinical-stage biotechnology company advancing innovative therapies for high incidence immuno-dermatological ...
Aspen Daily News

CAGE Bio Announces Start of Double-Blind Vehicle-Controlled Clinical Trial of Novel Topical DNA Aptamer Therapy CGB-600 for Vitiligo Treatment

SAN CARLOS, Calif. and DALLAS, Oct. 23, 2025 /PRNewswire/ -- CAGE Bio Inc., a clinical-stage biotechnology company pioneering novel immunomodulatory therapies for dermatological diseases, today ...